Surveal Pharma SRL
0.1 FTESurveal Pharma reported total assets of €5.47m at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026), with 0.1 full-time equivalent.
The score of Surveal Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +12 % Total assets -21 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Surveal Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 27 Aug 2025
- Year ended 31 Dec 2023filed on 10 Dec 2024
- Year ended 31 Dec 2022filed on 05 Jan 2024
- Year ended 31 Dec 2021filed on 26 Sep 2022
Surveal Pharma's financial analysis
- Solvency33.2%sector median: 32.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Surveal Pharma
Surveal Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0837.880.555
- VAT number
- BE0837880555
- Peppol
- Registered · 0208:0837880555 · as of 12 Nov 2026
- Legal form
- SRL
- Incorporated
- 12 Jul 2011
- Registered office
- 1050 Ixelles
- Size
- Micro · 0.1 FTE
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Surveal Pharma (SRL) has been based in Ixelles since 2011, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 431,161 € and equity of €1.82m; its revenue is not published. With 0.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 33.2%, above the median of its sector (32.3%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Surveal Pharma
Companies in the same business, of comparable size and area, outside its group.
- Alexion Pharma Belgium Manufacture of pharmaceutical preparations Brussels · balance sheet €8.68m
- Advanced Practical Diagnostics Manufacture of pharmaceutical preparations Turnhout · balance sheet €4.50m
- Laboratoires Lohmann & Rauscher Manufacture of pharmaceutical preparations Liège · balance sheet €4.03m
- MY®Health Manufacture of basic pharmaceutical products Lummen · balance sheet €2.56m
- Fortilab Manufacture of pharmaceutical preparations Etterbeek · balance sheet €1.39m
- Sasmar Pharmaceuticals Wholesale of pharmaceutical and medical goods Overijse · balance sheet €3.07m
- Green 2 Manufacture of basic pharmaceutical products Ostend · balance sheet €2.01m
- Cirba Wholesale of pharmaceutical and medical goods Ixelles · balance sheet 67,062 €
Frequently asked questions about Surveal Pharma
What is the revenue of Surveal Pharma?
Surveal Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Surveal Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0837880555 for Surveal Pharma, if the company is VAT-registered. Its company number (CBE) is 0837.880.555.
Where is the registered office of Surveal Pharma?
According to the CBE register, the registered office of Surveal Pharma is in 1050 Ixelles.
What is the equity of Surveal Pharma?
At the close of the 2025 financial year, the equity of Surveal Pharma amounts to 1,817,220 €, a solvency of 33.2% of total assets.
How many people work at Surveal Pharma?
0.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Surveal Pharma?
The register lists 1 active mandates at Surveal Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Surveal Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →